The role of MRS-assessed GABA in human behavioral performance.

Behavior Executive functions Magnetic resonance spectroscopy (MRS) Motor control Somatosensation Vision γ-aminobutyric acid (GABA)

Journal

Progress in neurobiology
ISSN: 1873-5118
Titre abrégé: Prog Neurobiol
Pays: England
ID NLM: 0370121

Informations de publication

Date de publication:
05 2022
Historique:
received: 02 10 2021
revised: 25 01 2022
accepted: 04 02 2022
pubmed: 13 2 2022
medline: 6 5 2022
entrez: 12 2 2022
Statut: ppublish

Résumé

Understanding the neurophysiological mechanisms that drive human behavior has been a long-standing focus of cognitive neuroscience. One well-known neuro-metabolite involved in the creation of optimal behavioral repertoires is GABA, the main inhibitory neurochemical in the human brain. Converging evidence from both animal and human studies indicates that individual variations in GABAergic function are associated with behavioral performance. In humans, one increasingly used in vivo approach to measuring GABA levels is through Magnetic Resonance Spectroscopy (MRS). However, the implications of MRS measures of GABA for behavior remain poorly understood. In this respect, it is yet to be determined how GABA levels within distinct task-related brain regions of interest account for differences in behavioral performance. This review summarizes findings from cross-sectional studies that determined baseline MRS-assessed GABA levels and examined their associations with performance on various behaviors representing the perceptual, motor and cognitive domains, with a particular focus on healthy participants across the lifespan. Overall, the results indicate that MRS-assessed GABA levels play a pivotal role in various domains of behavior. Even though some converging patterns emerge, it is challenging to draw comprehensive conclusions due to differences in behavioral task paradigms, targeted brain regions of interest, implemented MRS techniques and reference compounds used. Across all studies, the effects of GABA levels on behavioral performance point to generic and partially independent functions that refer to distinctiveness, interference suppression and cognitive flexibility. On one hand, higher baseline GABA levels may support the distinctiveness of neural representations during task performance and better coping with interference and suppression of preferred response tendencies. On the other hand, lower baseline GABA levels may support a reduction of inhibition, leading to higher cognitive flexibility. These effects are task-dependent and appear to be mediated by age. Nonetheless, additional studies using emerging advanced methods are required to further clarify the role of MRS-assessed GABA in behavioral performance.

Identifiants

pubmed: 35149113
pii: S0301-0082(22)00033-8
doi: 10.1016/j.pneurobio.2022.102247
pii:
doi:

Substances chimiques

gamma-Aminobutyric Acid 56-12-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102247

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Hong Li (H)

Movement Control & Neuroplasticity Research Group, Group Biomedical Sciences, KU Leuven, Belgium; KU Leuven Brain Institute (LBI), KU Leuven, Belgium. Electronic address: hong.li@kuleuven.be.

Kirstin-Friederike Heise (KF)

Movement Control & Neuroplasticity Research Group, Group Biomedical Sciences, KU Leuven, Belgium; KU Leuven Brain Institute (LBI), KU Leuven, Belgium; Department of Health Sciences and Research, Medical University of South Carolina, Charleston, SC, USA. Electronic address: kirstin.heise@kuleuven.be.

Sima Chalavi (S)

Movement Control & Neuroplasticity Research Group, Group Biomedical Sciences, KU Leuven, Belgium; KU Leuven Brain Institute (LBI), KU Leuven, Belgium. Electronic address: sima.chalavi@kuleuven.be.

Nicolaas A J Puts (NAJ)

MRC Centre for Neurodevelopmental Disorders, King's College London, London, UK; Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK. Electronic address: nicolaas.puts@kcl.ac.uk.

Richard A E Edden (RAE)

Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, USA. Electronic address: richardedden@gmail.com.

Stephan P Swinnen (SP)

Movement Control & Neuroplasticity Research Group, Group Biomedical Sciences, KU Leuven, Belgium; KU Leuven Brain Institute (LBI), KU Leuven, Belgium. Electronic address: stephan.swinnen@kuleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH